Literature DB >> 29737215

Needle-free cutaneous delivery of living human cells by Er:YAG fractional laser ablation.

Jing Yu1,2, Sachin Dubey2,3, Yogeshvar N Kalia2.   

Abstract

BACKGROUND: Dermatological diseases, including most skin cancers and rare genetic conditions frequently originate in the epidermis. Targeted, topical cell-based therapy is a promising therapeutic strategy. Here, we present the first report demonstrating that fractional laser ablation enables local 'needle-free' intraepidermal delivery of living human cells.
METHODS: The cells penetrated porcine ear skin via microchannels created by Er:YAG fractional laser ablation; cell delivery was quantified using a haemocytometer. Cutaneous distribution was confirmed visually by laser scanning confocal microscopy and histological analysis.
RESULTS: Total cell delivery (sum of amounts permeated and deposited) after 24 h increased from 5.7 ± 0.1 x105 to 9.6 ± 1.6 x105 cells/cm2 when increasing pore density from 300 to 600 pores/cm2, - corresponding to 19- and 32-fold increases over the control. At 600 pores/cm2, cell deposition was 136-fold greater than cell permeation - the latter most likely due to transport from micropores into appendageal pathways. Production of GFP post-delivery confirmed cell remained viability.
CONCLUSION: The results demonstrate the feasibility of using controlled laser microporation to achieve local 'needle-free' cutaneous delivery of living human cells to the epidermis and dermis. This raises the possibility of using this technique for targeted new approaches for dermatological therapy in these regions.

Entities:  

Keywords:  Er:YAG laser; Topical delivery; cell therapy; epidermis; fractional laser ablation; living cells; skin

Mesh:

Year:  2018        PMID: 29737215     DOI: 10.1080/17425247.2018.1472570

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  5 in total

1.  Laser facilitates week-long sustained transdermal drug delivery at high doses.

Authors:  Prateek Kakar; Zhuofan Li; Yibo Li; Yan Cao; Xinyuan Chen
Journal:  J Control Release       Date:  2020-01-07       Impact factor: 9.776

2.  Specific protein-protein interactions limit the cutaneous iontophoretic transport of interferon beta-1B and a poly-ARG interferon beta-1B analogue.

Authors:  S Dubey; R Perozzo; L Scapozza; Y N Kalia
Journal:  Int J Pharm X       Date:  2020-07-08

Review 3.  Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis.

Authors:  Ning Li; Yeping Qin; Dan Dai; Pengyu Wang; Mingfei Shi; Junwei Gao; Jinsheng Yang; Wei Xiao; Ping Song; Ruodan Xu
Journal:  Front Bioeng Biotechnol       Date:  2022-01-24

4.  Effect of mRNA Delivery Modality and Formulation on Cutaneous mRNA Distribution and Downstream eGFP Expression.

Authors:  Aditya R Darade; Maria Lapteva; Thomas Hoffmann; Markus Mandler; Achim Schneeberger; Yogeshvar N Kalia
Journal:  Pharmaceutics       Date:  2022-01-08       Impact factor: 6.321

5.  Phase I Study to Assess Safety of Laser-Assisted Topical Administration of an Anti-TNF Biologic in Patients With Chronic Plaque-Type Psoriasis.

Authors:  Martin Bauer; Edith Lackner; Peter Matzneller; Valentin Al Jalali; Sahra Pajenda; Vincent Ling; Christof Böhler; Werner Braun; Reinhard Braun; Maximilian Boesch; Patrick M Brunner; Markus Zeitlinger
Journal:  Front Med (Lausanne)       Date:  2021-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.